Friday, October 30, 2026
ExploreSearch
Finance Via News
Via News Knowledge File

Oracle Corporation

organization80% conf.·synced Oct 30, 2026

Technology company that adopted Custom AI Companion for global workforce AI assistants

60
sourced metrics
779
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High
281.40USD
Oct 22, 2026reference only
Stock Price
125.54USD
Oct 22, 2026reference only
Price 52 Week Low
114.99USD
Oct 22, 2026reference only
Market Cap
361614329340USD
Oct 22, 2026reference only
Stock Return Ytd
-35.9%
Oct 22, 2026reference only
Shares Outstanding
2880471000.0shares
Jun 12, 2026reference only
Cash
31289000000.0USD
May 31, 2026reference only
Total Assets
261759000000.0USD
May 31, 2026reference only
Revenue
67357000000.0USD
May 31, 2026reference only
Operating Cash Flow
31977000000.0USD
May 31, 2026reference only
Capex
55663000000.0USD
May 31, 2026reference only
Stockholders Equity
42508000000.0USD
May 31, 2026reference only
Net Income
17087000000.0USD
May 31, 2026reference only
Eps
5.83USD_per_share
May 31, 2026reference only
Rd Expense
10272000000.0USD
May 31, 2026reference only
Operating Income
20606000000.0USD
May 31, 2026reference only

Stated objectives

Oracle plans to raise up to $50 billion for cloud buildout

source
target: 50 billion USD by 2026-12-31 00:00:00stated

Raise capex forecast to around $50 billion for AI data centers

source
target: 50 billion USD stated

Oracle Cloud Infrastructure revenue growth

source
target: 4.1 billion USD (68% climb) stated

Build AI data centers

source
target: 50 billion USD capex stated

Oracle launched AI-driven supply chain tools to predict disruptions and optimize inventory levels

source
by 2025-01-01 00:00:00stated

Oracle targets continued cloud acceleration and data center capacity expansion in FY2026

source
stated

Capital spending on AI infrastructure

source
target: 500+ billion USD by 2026-01-01 00:00:00stated

Accelerate revenue and profit growth through AI infrastructure capital expenditure

source
stated

Spend on CapEx right before it starts generating revenue

source
stated

Increased guidance for 2027 revenues by $4 billion

source
target: 4 billion USD increase by 2027-01-01 00:00:00stated

Relationship graph · 779 connections

Competes with
136
Developed by
107
Covered by
97
Customer of
75
Supplies to
68
Employs
38
located in
27
headquartered in
23

Via News coverage

Pershing Square Builds Microsoft Stake as Oracle Borrows to Fund AI Data Centers
May 17, 2026
CFO AI Budgets Set to Surge 50%+ as Numero AI, BlackLine, and Oracle Race to Automate Corporate Finance
May 17, 2026
BlackLine, Oracle, and Numero AI Deploy Autonomous Agents as CFOs Plan 50%-Plus AI Budget Increases
May 15, 2026
BlackLine Launches Agentic Finance Platform as Oracle Deploys AI Across Fusion Cloud
May 13, 2026
Dell, SAP, Oracle Race to Own Enterprise AI Control Layer as Model Commoditization Accelerates
April 28, 2026
BlackLine and Oracle Race to Embed Autonomous AI Agents in Enterprise Finance
April 27, 2026
Dell, NVIDIA, Oracle Fight to Own Enterprise AI Stack as Domain Expertise Displaces Model Access
April 27, 2026
BlackLine, Oracle, and OneStream Converge on Agentic AI as CFO Autonomy Becomes the 2026 Battleground
April 26, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com